Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD

Autor: Arthur Y. Kim, Ming V. Lin, Joseph Brancale, Raymond T. Chung, Guillermo Ortiz, Nneka N. Ufere, Ravi Thadhani, Elke S. Backman, Gregory L. Hundemer, Jessica Wisocky, Dihua Xu, Donald F. Chute, Meghan E. Sise
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Male
medicine.medical_specialty
Cirrhosis
Time Factors
Sofosbuvir
Sustained Virologic Response
Epidemiology
Hepatitis C virus
030232 urology & nephrology
Renal function
Hepacivirus
urologic and male genital diseases
Critical Care and Intensive Care Medicine
medicine.disease_cause
Kidney
Antiviral Agents
03 medical and health sciences
0302 clinical medicine
Risk Factors
Internal medicine
medicine
Albuminuria
Humans
Renal Insufficiency
Chronic
Aged
Retrospective Studies
Transplantation
business.industry
Editorials
Retrospective cohort study
Hepatitis C
Original Articles
Middle Aged
medicine.disease
female genital diseases and pregnancy complications
Regimen
Treatment Outcome
Nephrology
Cohort
030211 gastroenterology & hepatology
Drug Therapy
Combination
Female
business
medicine.drug
Glomerular Filtration Rate
Popis: Background and objectives Hepatitis C virus infection is common in patients with CKD and leads to accelerated progression to ESRD. Sofosbuvir is a potent direct-acting antiviral therapy against hepatitis C virus; however, there are concerns about its safety in patients with CKD. The objective of our study was to determine the safety and efficacy of sofosbuvir in patients with CKD. Design, setting, participants, & measurements We studied a retrospective observational cohort of patients with CKD defined by eGFR Results Ninety-eight patients with CKD (42% stage 1 or 2 CKD and 58% stage 3 CKD) were included. Mean age was 62 years old, 78% were men, and 65% were white. Additionally, 49% of patients had diabetes, 38% of patients had cirrhosis, and 33% of patients had prior solid organ transplant. Overall sustained virologic response was 81% and varied by regimen used and viral genotype. Average baseline eGFR was equivalent to average on-treatment eGFR, but seven patients experienced a rise in creatinine ≥1.5 times baseline while taking sofosbuvir; all but one recovered. In patients with eGFR Conclusions Sofosbuvir-based direct-acting antiviral therapy is safe and effective in a cohort of patients with CKD infected with hepatitis C.
Databáze: OpenAIRE
Externí odkaz: